References
Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15(6):385–403.
Erinjeri JP, Fong AJ, Kemeny NE, Brown KT, Getrajdman GI, et al. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer. 2011;117(6):1296–301.
Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–73.
Chiorean EG, Hurwitz HI, Cohen RB, Schwartz JD, Dalal RP, et al. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol. 2015;26(6):1230–7.
Ueda S, Satoh T, Gotoh M, Gao L, Doi T. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas. Oncologist. 2015;20(5):493–4.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors report no conflicts of interest.
Rights and permissions
About this article
Cite this article
Zhan, C., Deipolyi, A.R. & Erinjeri, J.P. Wound Healing Failure Following Venous Access Chest Port Placement Associated with Ramucirumab Therapy. Cardiovasc Intervent Radiol 40, 1804–1806 (2017). https://doi.org/10.1007/s00270-017-1752-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-017-1752-8